Spray-On Skin Cells Heal Leg Ulcers

Featured Article
Academic Journal
Main Category: Dermatology
Also Included In: Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 03 Aug 2012 - 2:00 PDT

Current ratings for:
Spray-On Skin Cells Heal Leg Ulcers


Patient / Public: not yet rated
Healthcare Prof: not yet rated

Spraying living skin cells directly onto the wound was found to heal venous leg ulcers better than standard care, according to the results of a trial published online first in The Lancet on Friday.

The phase 2b clinical trial tested a "spray-on skin" that is under development for the treatment of venous leg ulcers. It contains two types of living, growth-arrested skin cells, keratinocytes and fibroblasts.

The treatment, which is described as an "allogeneic living cell bioformulation" is being developed by Healthpoint Biotherapeutics of Fort Worth, Texas.

The bioformulation, called HP802-247, contains a particular combination of keratinocytes and fibroblasts, which are thought to interact with the patient's own cells to promote wound healing and tissue regeneration.

Results of previous lab culture experiments suggest they release various growth factors and cytokines into the wound environment, said the company in a statement.

About 2.5 million Americans suffer from leg ulcers, an increasingly common condition where circulation in the lower legs is so poor, usually because of damaged veins or valves or both, that it leads to open wounds or ulcers that are very slow to heal and often recur, developing into chronic non-healing wounds.

The trial, which took place in 28 centers in the US and Canada, tested the effectiveness of two concentrations and dosing frequencies of the treatment when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week period.

228 patients were randomly assigned in a double blind manner to receive one of four doses (5·0 x 10 million cells per mL every 7 days or every 14 days, or 0·5 x 10 million cells per mL every 7 days or every 14 days), or the control formulation (vehicle alone every 7 days). (Double blind means neither the patients nor the professionals who administered the treatment knew whether they were using the active agent or the control).

Each patient had up to three venous leg ulcers, with diagnosis confirmed by ultrasound, and with at least one ulcer measuring between 2 and 12 square cm in area, that had persisted for between 4 and 104 weeks.

The primary measure of success was the average change in wound area by the end of week 12.

Overall, the spray-on skin achieved statistically significant improvement, as compared with control plus standard care.

The authors write there was a "significantly greater mean reduction in wound area associated with active treatment", with the "0·5 x 10 million cells/mL every 14 days showing the largest improvement compared with vehicle".

The most frequently reported adverse events were skin ulcers, cellulitis, wound infection, and skin irritation. These were much the same in all groups.

The authors conclude that at the appropriate dose, "venous leg ulcers can be healed with a spray formulation of allogeneic neonatal keratinocytes and fibroblasts without the need for tissue engineering".

In an accompanying commentary, Matthias Augustin, of the University of Hamburg, and Wolfgang Vanscheidt, of Dermatologische Praxisgemeinschafts in Freiberg, Germany, note that:

"In a well-done clinical trial in The Lancet, Robert Kirsner and colleagues have clearly shown that a specific cell therapy for venous leg ulcers can lead to a significantly higher healing rate than for vehicle alone in hard-to-heal [venous] wounds for which compression treatment has been applied unsuccessfully."

Written by Catharine Paddock PhD
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our dermatology section for the latest news on this subject.
"Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial"; Robert S Kirsner, William A Marston, Robert J Snyder, Tommy D Lee, D Innes Cargill, Herbert B Slade; The Lancet, 3 August 2012; DOI: 10.1016/S0140-6736(12)60644-8; Link to Abstract.
Additional source: Healthpoint Biotherapeutics..
Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Spray-On Skin Cells Heal Leg Ulcers." Medical News Today. MediLexicon, Intl., 3 Aug. 2012. Web.
3 Aug. 2012. <http://www.medicalnewstoday.com/articles/248586.php>


APA
n.p. (2012, August 3). "Spray-On Skin Cells Heal Leg Ulcers." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/articles/248586.php.

Please note: If no author information is provided, the source is cited instead.



'Spray-On Skin Cells Heal Leg Ulcers'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Adult Webcams